Here, the authors identify a reliance of CML LSCs on low P53 expression for self-renewal and therapeutically target this by combining an MDM2 inhibitor with TKI in preclinical models of CML. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.